Abraxis Bioscience Inc. (New) (ABII)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

11755 WILSHIRE BLVD., 20TH FLOOR LOS ANGELES, CA 90025

Abraxis Bioscience, Inc., a biotechnology company, delivers therapeutics and core technologies that offer patients and medical professionals treatments for cancer and other critical illnesses. It primarily focuses on an array of oncology drug candidates and a cardiovascular portfolio. The Abraxis portfolio includes protein-based nanoparticle chemotherapeutic compound, ABRAXANE, which is based on its proprietary tumor targeting system, known as the nab technology platform. The company also develops a pipeline, which includes further investigation with ABRAXANE, as well as other drug candidates. Its other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of solid tumors; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of solid tumors; and Coroxane for the treatment of coronary artery restenosisis. The company is headquartered in Los Angeles, California.

View SEC Filings from ABII instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ABII (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ABII BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SOON SHIONG PATRICK EXECUTIVE CHAIRMAN

  • Officer
  • Director
  • 10% Owner
No longer subject to file 2010-10-15 0

CHEN DAVID

  • Director
No longer subject to file 2010-10-15 0

WENDEL BRUCE CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
No longer subject to file 2010-10-15 0

PATRICK SOON-SHIONG 2009 GRANTOR RETAINED ANNUITY TRUST 1 UAD 9/24/2009

  • 10% Owner
No longer subject to file 2010-10-15 0

PATRICK SOON-SHIONG 2009 GRANTOR ANNUITY TRUST 2 UAD 9/24/2009

  • 10% Owner
No longer subject to file 2010-10-15 0

MICHELE B. SOON-SHIONG 2009 GRANTOR RETAINED ANNUITY TRUST 2 UAD 9/24/2009

  • 10% Owner
No longer subject to file 2010-10-15 0

MICHELE B. SOON-SHIONG 2009 GRANTOR RETAINED ANNUITY TRUST 1 UAD 9/24/2009

  • 10% Owner
No longer subject to file 2010-10-15 0

SHAPIRO LEONARD

  • Director
No longer subject to file 2010-10-15 0

NIMER STEPHEN

  • Director
No longer subject to file 2010-10-15 0

CALHOUN KIRK K

  • Director
No longer subject to file 2010-10-15 0

SITRICK MICHAEL S

  • Director
No longer subject to file 2010-10-15 0

FOGELMAN MITCHELL K CHIEF FINANCIAL OFFICER

  • Officer
  • Director
No longer subject to file 2010-10-15 0

CELGENE CORP /DE/

ARTISTRY ACQUISITION CORP.

  • 10% Owner
100 2010-10-15 0

RODGERS RICHARD J SENIOR VICE PRESIDENT AND CFO

  • Officer
15,000 2009-07-13 0

HEDLEY MARY LYNNE EXECUTIVE VP OF OPS & CSO

  • Officer
25,000 2009-07-13 0

MOULDER LEON O JR PRESIDENT & CEO

  • Officer
  • Director
0 2009-04-29 0

O'TOOLE DAVID D. CFO & EXECUTIVE VP

  • Officer
1,654 2009-03-02 0

GEEHR ED EXECUTIVE VP OPERATIONS

  • Officer
841 2009-03-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments